Physician profile
Marsha A Mccormick
NPI 1164663845
$19,694.56
in general payments reported to CMS, 2019-2025
57 companies · $2,918 in 2025
The $2,918 reported for 2025 was more than what a typical Neuroscience (Registered Nurse) provider received nationally (typical 2025 total: $185).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,779 · 2022: $3,087 · 2023: $3,026 · 2024: $4,884 · 2025: $2,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,200 · Consulting Fee: $1,500 · Travel and Lodging: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,200.19 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $128.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,800.75 | 2021-2025 | |
| Amgen INC. | $3,266.64 | 2021-2025 | Uplizna, Aimovig |
| Ucb, INC. | $1,292.37 | 2021-2025 | Briviact, Rystiggo, Zilbrysq |
| Biogen, INC. | $1,088.03 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $666.91 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $637.61 | 2022-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Sk Life Science, INC. | $625.19 | 2022-2025 | |
| Lundbeck LLC | $616.77 | 2021-2025 | Vyepti |
| Argenx US, INC. | $540.69 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurocrine Biosciences, INC. | $423.55 | 2021-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $412.61 | 2021-2025 | Nuplazid |
| Lilly USA, LLC | $395.33 | 2021-2025 | Emgality, Amyvid, Kisunla |
| Novartis Pharmaceuticals Corporation | $332.86 | 2024-2025 | |
| Celgene Corporation | $282.18 | 2021-2024 | Zeposia |
| Neurelis, INC. | $258.76 | 2021-2024 | Valtoco |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marsha Mccormick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.